Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas

Modern Pathology

Volumn 29, Issue 12, 2016, Pages 1586-1593

  Coatham, Mackenzie ^a   Li, Xiaodong ^a   Karnezis, Anthony N ^b   Hoang, Lien N ^b,c   Tessier Cloutier, Basile ^b   Meng, Bo ^a   Soslow, Robert A ^c   Blake Gilks, C ^b   Huntsman, David G ^b   Stewart, Colin J R ^d   Postovit, Lynne M ^a   Köbel, Martin ^e   Lee, Cheng Han ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARID1A PROTEIN; ARID1B PROTEIN; BRG1 PROTEIN; PROTEIN; PROTEIN SWI; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; ARID1B PROTEIN, HUMAN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL DEDIFFERENTIATION; CLINICAL ARTICLE; DNA BINDING; ENDOMETRIUM CARCINOMA; FEMALE; FRAMESHIFT MUTATION; GENE DISRUPTION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NONSENSE MUTATION; OVARIAN DEDIFFERENTIATED CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TRANSCRIPTION REGULATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; GENETICS; OVARY TUMOR; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, ENDOMETRIOID; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84983755442     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.156     Document Type: Article

References (27)

1. Silva EG, Deavers MT, Bodurka DC, et al. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 2006;25:52-58.
2. Tafe LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 2010;23:781-789.
3. Karnezis AN, Hoang LN, Coatham M, et al. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol 2016;29:302-314.
4. Kuhn E, Ayhan A, Bahadirli-Talbott A, et al. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am J Surg Pathol 2014;38:660-665.
5. Berretta R, Patrelli TS, Faioli R, et al. Dedifferentiated endometrial cancer: an atypical case diagnosed from cerebellar and adrenal metastasis: case presentation and review of literature. Int J Clin Exp Pathol 2013;6: 1652-1657.
6. Vita G, Borgia L, Di Giovannantonio L, et al. Dedifferentiated endometrioid adenocarcinoma of the uterus: a clinicopathologic study of a case. Int J Surg Pathol 2011;19:649-652.
7. Strehl JD, Wachter DL, Fiedler J, et al. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant. Ann Diagn Pathol 2015;19:198-202.
8. Stewart CJ, Crook ML. SWI/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma. Pathology 2015;47:439-445.
9. Ramalingam P, Masand RP, Euscher ED, et al. Undifferentiated carcinoma of the endometrium: an expanded immunohistochemical analysis including PAX-8 and basal-like carcinoma surrogate markers. Int J Gynecol Pathol 2016;35:410-418.
10. Li Z, Zhao C. Clinicopathologic and immunohistochemical characterization of dedifferentiated endometrioid adenocarcinoma. Appl Immunohistochem Mol Morphol 2015; e-pub ahead of print.
11. Chen L, Pang S, Shen Y, et al. Low-grade endometrioid carcinoma of the ovary associated with undifferentiated carcinoma: case report and review of the literature. Int J Clin Exp Pathol 2014;7:4422-4427.
12. Hoang LN, Lee YS, Karnezis AN, et al. Immunophenotypic features of dedifferentiated endometrial carcinoma Insights from BRG1/INI1-deficient tumors. Histopathology 2016; doi:10. 1111/his. 12989; e-pub ahead of print.
13. Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: a review. Pathology 2007;39:134-138.
14. Kobel M, Meng B, Hoang LN, et al. Molecular analysis of mixed endometrial carcinomas shows clonality in most cases. Am J Surg Pathol 2016;40:166-180.
15. Hoang LN, McConechy MK, Meng B, et al. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology 2015;66:664-674.
16. Hoang LN, Han G, McConechy M, et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma-diagnostic utility of HNF-1beta and oestrogen receptor. Histopathology 2014;64:585-596.
17. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2014;43:D805-D811.
18. Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci Adv 2015;1: e1500447.
19. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11:481-492.
20. Helming KC, Wang X, Wilson BG, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 2014;20:251-254.
21. Chan N, Bristow RG. "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res 2010;16:4553-4560.
22. Hoffman GR, Rahal R, Buxton F, et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci USA 2014;111:3128-3133.
23. Oike T, Ogiwara H, Tominaga Y, et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res 2013;73:5508-5518.
24. Reisman DN, Sciarrotta J, Wang W, et al. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003;63:560-566.
25. Karnezis AN, Wang Y, Ramos P, et al. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcemic type. J Pathol 2016;238:389-400.
26. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012;33:100-103.
27. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011;43: 1219-1223.